Abstract
RNASEL (encoding ribonuclease L) has recently been proposed as a candidate for the hereditary prostate cancer (HPC1) gene. We determined that the RNASEL variant Arg462Gln has three times less enzymatic activity than the wildtype and is significantly associated with prostate cancer risk (P = 0.007). At least one copy of the mutated allele that causes this substitution is carried by nearly 60% of the men in our study. Men that are heterozygous with respect to the mutated allele have 50% greater risk of prostate cancer than non-carriers, and homozygotes have more than double the risk.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Hassel, B.A. et al. EMBO. J 12, 3297–3304 (1993).
Zhou, A. et al. EMBO. J 16, 6355–6363 (1997).
Kerr, I.M. & Brown, R.E. Proc. Natl Acad. Sci. USA 75, 256–260 (1978).
Carpten, J. et al. Nature Genet. 30, 181–184 (2002).
Newton, C.R. et al. Nucleic Acids Res. 17, 2503–2516 (1989).
Ferrie, R.M. et al. Am. J. Hum. Genet. 51, 251–262 (1992).
Greenland, S. & Robins, J.M. Am. J. Epidemiol. 128, 1185–1197 (1988).
Eeles, R.A. et al. Am. J. Hum. Genet. 62, 653–658 (1998).
Xu, J. Am. J. Hum. Genet. 66, 945–957 (2000).
Rennert, H. et al. Am. J. Hum. Genet. 71, 981–984 (2002).
Rokman, A. et al. Am. J. Hum. Genet. 70, 1299–1304 (2002).
Wang, L. et al. Am. J. Hum. Genet. 71, 116–123 (2002).
Acknowledgements
This work was supported by grants from the US National Institutes of Health, Department of Defense, the Urologic Research Foundation and General Motors Foundation.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Casey, G., Neville, P., Plummer, S. et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet 32, 581–583 (2002). https://doi.org/10.1038/ng1021
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ng1021
This article is cited by
-
CRISPR/Cas9 model of prostate cancer identifies Kmt2c deficiency as a metastatic driver by Odam/Cabs1 gene cluster expression
Nature Communications (2024)
-
Carriage of mutations R462Q (rs 486907) and D541E (rs 627928) of the RNASEL gene and risk factors in patients with prostate cancer in Burkina Faso
BMC Medical Genomics (2022)
-
MAGPEL: an autoMated pipeline for inferring vAriant-driven Gene PanEls from the full-length biomedical literature
Scientific Reports (2020)
-
Characterisation of microbial communities within aggressive prostate cancer tissues
Infectious Agents and Cancer (2017)
-
Association of variants in genes related to the immune response and obesity with BPH in CLUE II
Prostate Cancer and Prostatic Diseases (2014)